Efficacy of ProgenaMatrix™ in the Management of DFUs

Inclusion Criteria: * Understands and agrees that the standard treatment protocol will include the application of ProgenaMatrix™ as the standard of care for this project. * Have participated in the informed consent process and signed a data collection and treatment specific informed consent. * Be able and willing to comply with the data collection procedures, data collection visits, dressings, and off-loading. * Have type I or type II diabetes mellitus with an Investigator-confirmed glycosylated hemoglobin (HBA1c) of less than or equal to 11.5% within 3 months prior treatment. * Have at least one DFU Ulcer that has been in existence for a minimum of 4 weeks but no more than 12 months and meets all the following criteria: * Ulcer is partial or full thickness without capsule/tendon/bone exposure. * Ulcer is on the foot or ankle. * Ulcer area is greater than 1 sq. cm. but less than 18 sq. cm. post debridement. (Ulcers larger than 18 sq. cm. can be included with the approval of the Medical Monitor.) * If the subject has more than one ulcer the data collection ulcer will be at the discretion of the Investigator. * There is minimum of 1 cm between the ulcer treated and any other ulcer on the same foot. * Have adequate vascular perfusion of the affected limb as defined by one of the following in order of preference. * Ankle-Brachial index of greater than .65 and less the 1.3 * Toe Pressure of greater than 40 mmHg * TcPO2 of greater than 40 mmHg * Patient had vascu…